The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles

Hyperprogressive disease (HPD), an aggressive acceleration of tumor growth, was observed in a group of cancer patients treated with anti-PD1/PDL1 antibodies. The presence of a peculiar macrophage subset in the tumor microenvironment is reported to be a sort of “immunological prerequisite” for HPD development. These macrophages possess a unique phenotype that it is not clear how they acquire. We hypothesized that certain malignant cells may promote the induction of an “HPD-related” phenotype in macrophages. Bone-marrow-derived macrophages were exposed to the conditioned medium of five non-small cell lung cancer cell lines. Macrophage phenotype was analyzed by microarray gene expression profile and real-time PCR. We found that human NSCLC cell lines, reported as undergoing HPD-like tumor growth in immunodeficient mice, polarized macrophages towards a peculiar pro-inflammatory phenotype sharing both M1 and M2 features. Lipid-based factors contained in cancer cell-conditioned medium induced the over-expression of several pro-inflammatory cytokines and the activation of innate immune receptor signaling pathways. We also determined that tumor-derived Extracellular Vesicles represent the main components involved in the observed macrophage re-education program. The present study might represent the starting point for the future development of diagnostic tools to identify potential hyperprogressors.

[1]  T. Haykal,et al.  Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti–PD-1 immunotherapy , 2022, Science Translational Medicine.

[2]  J. Minna,et al.  Tumor cells modulate macrophage phenotype in a novel in vitro co-culture model of the non-small cell lung cancer tumor microenvironment. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  N. Sun,et al.  Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer , 2022, BMC Medicine.

[4]  Bosen You,et al.  Tumor-associated macrophage-derived exosomes transmitting miR-193a-5p promote the progression of renal cell carcinoma via TIMP2-dependent vasculogenic mimicry , 2022, Cell Death & Disease.

[5]  Yangchun Chen,et al.  miR-146a promotes M2 macrophage polarization and accelerates diabetic wound healing by inhibiting the TLR4/NF-κB axis. , 2022, Journal of molecular endocrinology.

[6]  Y. Chan,et al.  Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature , 2022, Frontiers in Immunology.

[7]  Jun Zhang,et al.  Targeting interleukin-1β and inflammation in lung cancer , 2022, Biomarker research.

[8]  J. Weiss,et al.  Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma , 2022, Frontiers in Oncology.

[9]  C. D’Souza-Schorey,et al.  Tumor-Derived Extracellular Vesicles: A Means of Co-opting Macrophage Polarization in the Tumor Microenvironment , 2021, Frontiers in Cell and Developmental Biology.

[10]  P. Allavena,et al.  Macrophages and cancer stem cells: a malevolent alliance , 2021, Molecular Medicine.

[11]  E. Tagliabue,et al.  Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression , 2021, Frontiers in Cell and Developmental Biology.

[12]  M. D. Peris-Díaz,et al.  Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy , 2021, Cancers.

[13]  M. Colombo,et al.  Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain , 2021, Cancers.

[14]  J. Iovanna,et al.  NUPR1: A Critical Regulator of the Antioxidant System , 2021, Cancers.

[15]  D. Chan,et al.  The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression , 2021, International journal of molecular sciences.

[16]  W. Jiang,et al.  NUPR1 and its potential role in cancer and pathological conditions (Review). , 2021, International journal of oncology.

[17]  G. Kroemer,et al.  NUPR1 is a critical repressor of ferroptosis , 2021, Nature Communications.

[18]  S. Ramaswamy,et al.  Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models , 2021, mAbs.

[19]  Lianmei Zhao,et al.  Exosome-mediated communication between tumor cells and tumor-associated macrophages: implications for tumor microenvironment , 2021, Oncoimmunology.

[20]  D. Lambrechts,et al.  IL1β Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D , 2020, Cancer Immunology Research.

[21]  T. Hirano IL-6 in inflammation, autoimmunity and cancer , 2020, International immunology.

[22]  Ting Zhang,et al.  Tumor-Associated Macrophages in Tumor Immunity , 2020, Frontiers in Immunology.

[23]  C. Moscheni,et al.  Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know , 2020, Journal of experimental & clinical cancer research : CR.

[24]  A. Leelahavanichkul,et al.  Over-expression of miR-223 induces M2 macrophage through glycolysis alteration and attenuates LPS-induced sepsis mouse model, the cell-based therapy in sepsis , 2020, PloS one.

[25]  M. Bosco,et al.  Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1) , 2020, Cancers.

[26]  D. Matei,et al.  MicroRNA-155 Implication in M1 Polarization and the Impact in Inflammatory Diseases , 2020, Frontiers in Immunology.

[27]  Xikun Zhou,et al.  Tumor-Associated Macrophages: Recent Insights and Therapies , 2020, Frontiers in Oncology.

[28]  S. Dubinett,et al.  The Role of Interleukin 1β in the Pathogenesis of Lung Cancer , 2020, JTO clinical and research reports.

[29]  Raghu Kalluri,et al.  The biology, function, and biomedical applications of exosomes , 2020, Science.

[30]  A. Morgan,et al.  Standardized protocols for differentiation of THP-1 cells to macrophages with distinct M(IFNγ+LPS), M(IL-4) and M(IL-10) phenotypes. , 2020, Journal of immunological methods.

[31]  M. Koch,et al.  Hot EVs - how temperature affects extracellular vesicles. , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[32]  Xiaoying Dong,et al.  Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages , 2019, Journal of immunology research.

[33]  S. Castiglioni,et al.  3D Quantitative and Ultrastructural Analysis of Mitochondria in a Model of Doxorubicin Sensitive and Resistant Human Colon Carcinoma Cells , 2019, Cancers.

[34]  N. Meyer,et al.  The TNF Paradox in Cancer Progression and Immunotherapy , 2019, Front. Immunol..

[35]  Feng-ming Ding,et al.  CXCR4 knockdown prevents inflammatory cytokine expression in macrophages by suppressing activation of MAPK and NF-κB signaling pathways , 2019, Cell & Bioscience.

[36]  F. Greten,et al.  Inflammation and Cancer: Triggers, Mechanisms, and Consequences. , 2019, Immunity.

[37]  Yuan He,et al.  The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation , 2019, International journal of molecular sciences.

[38]  Haiyang Xie,et al.  Blocking Triggering Receptor Expressed on Myeloid Cells‐1‐Positive Tumor‐Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti‐Programmed Cell Death Ligand 1 Resistance in Liver Cancer , 2019, Hepatology.

[39]  M. Broggini,et al.  LKB1 deficiency renders non-small-cell lung cancer cells sensitive to ERK inhibitors.: ERK inhibitors in LKB1 mutated NSCLC. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[40]  Jiao Guo,et al.  M2b macrophage polarization and its roles in diseases , 2018, Journal of leukocyte biology.

[41]  K. Khazim,et al.  The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice , 2018, Oncology and Therapy.

[42]  D. Djureinovic,et al.  Expression of scavenger receptor MARCO defines a targetable tumor‐associated macrophage subset in non‐small cell lung cancer , 2018, International journal of cancer.

[43]  V. Torri,et al.  Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade , 2018, Clinical Cancer Research.

[44]  J. Tosello,et al.  Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology , 2018, Front. Immunol..

[45]  M. Dessing,et al.  TREM‐1 and its potential ligands in non‐infectious diseases: from biology to clinical perspectives , 2017, Pharmacology & therapeutics.

[46]  A. Longatto-Filho,et al.  High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer , 2017, PloS one.

[47]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[48]  S. Snapper,et al.  Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages , 2017, Science.

[49]  Lin-lin Sun,et al.  2-Deoxyglucose Suppresses ERK Phosphorylation in LKB1 and Ras Wild-Type Non-Small Cell Lung Cancer Cells , 2016, PloS one.

[50]  Charles Ferté,et al.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.

[51]  Yutian Li,et al.  MiRNA-Mediated Macrophage Polarization and its Potential Role in the Regulation of Inflammatory Response , 2016, Shock.

[52]  B. Brüne,et al.  Lipocalin 2 from macrophages stimulated by tumor cell–derived sphingosine 1-phosphate promotes lymphangiogenesis and tumor metastasis , 2016, Science Signaling.

[53]  S. Hanash,et al.  IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer. , 2016, Cancer research.

[54]  S. Safe,et al.  MicroRNA-223 is a crucial mediator of PPARγ-regulated alternative macrophage activation. , 2015, The Journal of clinical investigation.

[55]  Xiaojun Liu,et al.  Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer , 2015, Clinical Cancer Research.

[56]  S. Tsai,et al.  EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82. , 2015, Biochimica et biophysica acta.

[57]  M. Kortylewski,et al.  Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB , 2014, Scientific Reports.

[58]  L. Boon,et al.  Lipocalin 2 deactivates macrophages and worsens pneumococcal pneumonia outcomes. , 2013, The Journal of clinical investigation.

[59]  James A. Hutchinson,et al.  IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[60]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[61]  M. Meyerson,et al.  Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients , 2008, British Journal of Cancer.

[62]  Jill P. Mesirov,et al.  GSEA-P: a desktop application for Gene Set Enrichment Analysis , 2007, Bioinform..

[63]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[64]  Marian F Young,et al.  The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. , 2005, The Journal of clinical investigation.

[65]  J. Mauël,et al.  CD69 and regulation of the immune function. , 1999, Immunopharmacology and immunotoxicology.

[66]  T. Oegema,et al.  A fragment of α-actinin promotes monocyte/macrophage maturation in vitro , 1999 .